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A B S T R A C T
Background: Over the past two decades, the use of image and performance enhancing drugs (IPEDs) has in-
creased significantly. Once largely confined to professional athletes, IPED use has transcended the elite sporting
arena and is now predominantly found among non-elite, recreational gym users. This paper presents research
findings from a qualitative study of IPED use and supply in a ‘hardcore’ bodybuilding gym in the north of
England. This article makes an original contribution to the field by providing an in-depth account of the use and
supply of IPEDs among this population, demonstrating the intersectionality that exists across IPEDs, diverted
medication and both licit and illicit substance use and supply.
Methods: The findings are based on the research team’s privileged access to an independent, ‘hardcore’ body
building gym in the north of England. Four fieldworkers undertook overt systematic observations, supplemented
by 20 semi-structured interviews.
Results: Amongst this sample of bodybuilders, substance use transcended IPEDs to encompass a much broader
cocktail of substances all who used IPEDs concomitantly used diverted medication as a means of negating an-
ticipated side-effects, and over half used illegal psychoactive drugs. Furthermore, virtually all of these substances
were available to buy via the gym, through fellow gym members and, at times, staff.
Conclusion: This article draws three main conclusions. (1) We are witnessing a convergence of IPED use and
supply with diverted medication and ‘traditional’ recreational substances. (2) The extensive poly-substance use
reported by interviewees in this sample necessitates a review of existing harm reduction advice for IPED users
that takes into consideration the full range of substances currently being used. (3) Punitive drug policy reform
that aims to reduce IPED markets needs to consider the potential to displace social supply towards more com-
mercially-driven dealing. Harsher drug laws may also risk criminalising and stigmatising IPED users.
Introduction
This paper enhances existing understandings of the intersectionality
that exists between Image and Performance Enhancing Drugs (IPEDs)1,
prescription medication and illicit drug use. We commence with a re-
view of contemporary research regarding IPED use and markets, before
sketching out the existing knowledge on polypharmacy. In doing so, we
assert that, while there is a corpus of research that has begun to
document the consumption of IPEDs, diverted medication and recrea-
tional drugs, this current knowledge is limited due its reliance on
survey data (e.g. Bates & McVeigh, 2016; Begley, McVeigh, & Hope,
2017; Brennan, Wells, & Van Hout, 2017; Sagoe et al., 2015). We argue
that further in-depth research is required if we are to fully understand
this emergent trend.
Through this paper, we seek to enhance the existing knowledge of
polypharmacy among IPED users by moving beyond the existing IPED
literature through the provision of a more holistic and in-depth account
of polypharmacy. To expound our understanding of the nature and
motivations of this polypharmacy, we provide a case study of a body-
building gym in the north of England - ‘Behemoth Builder Gym’- that
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1 IPED is a term used to refer to a range of substances that are designed to modify the function and appearance of the body (Bates & McVeigh, 2016). This class of
substances includes, among others, anabolic-androgenic steroids, growth hormones, peptides, tanning drugs, and weight loss substances (Bates & McVeigh, 2016;
Hope et al., 2013; Jennings et al., 2014).
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utilises ethnographic method. Drawing on data from 20 interviews and
field observations, we demonstrate that IPEDs were, for many of our
participants, part of an ever-growing repertoire of substances used by
‘traditional’ recreational drug users. Our findings encompass three
distinct elements of observed polypharmacy: the variation of IPEDs
used, the use of drugs intended to mitigate the negative side effects of
IPEDs, and the concurrent use of illegal psychoactive drugs. In high-
lighting the breadth of substances used and extensive drug-using re-
pertories we encountered, we go on to discuss the implications for
developing public health and targeted treatment interventions, in-
cluding appropriate harm reduction advice.
Further insight into polypharmacy amongst IPED users is provided
in the second section of our findings. Moving beyond the common focus
on use, we highlight how intersectionality is also present in relation to
drug supply. This is important as the relationship between which drugs
are consumed and the availability of drugs in local markets is seldom
considered. We illustrate how the supply of IPEDs in a marketplace is
intersected by the supply of various licit and illicit substances and di-
verted medications. We also demonstrate how, within our study site,
IPEDs were yet another prohibited commodity to be widely consumed,
traded and profited from. We assert that the wide availability and
subsequent consumption of this cocktail of substances presents dis-
tinctive challenges for the management of drug harms.
We conclude with a discussion of the wider implications of our re-
sults for harm reduction interventions and drug policies. In particular,
we discuss the implications of these findings for targeted treatment
interventions, public health policy and drug policy reform.
Background
Since the late 1980s, the use of IPEDs has increased significantly in
the UK (Antonopoulos & Hall, 2016; Bates & McVeigh, 2016; Begley
et al., 2017; McVeigh & Begley, 2017). Once largely confined to pro-
fessional athletes, IPED use has transcended the elite sporting arena and
is now predominantly found among non-elite, recreational gym users
(Coomber et al., 2015; Hanley Santos & Coomber, 2017; McVeigh,
Bates, & Chandler, 2015, p. 2; Van Hout & Kean, 2015). Estimates from
the Crime Survey for England and Wales (CSEW) show that use of
anabolic-androgenic steroids (AAS) – the most commonly used IPED –
has increased from 170,000 in 2001/02 to 356,000 in 2016/17 (Home
Office, 2017). Further, as Begley et al. (2017) note, the CSEW is likely
to underestimate the actual number of users, with data from needle and
syringe exchange (NSE) programmes – which suggests that IPED use has
grown at a more significant rate (see, for example, McVeigh & Begley,
2017) – being a more accurate predictor. As a result, the profile of IPED
users has also become increasingly diverse (Cohen, Collins, Darkes, &
Gwartney, 2007; Kimergård & McVeigh, 2014; Sagoe et al., 2015;
Zahnow et al., 2018), and whilst attempts have been made to construct
a typology of users (e.g. Christiansen, Vinther, & Liokaftos, 2017), there
is a consensus within the literature that this is becoming ever more
difficult. Existing research demonstrates that motivations for, and ex-
periences of, using IPEDs are vast (Antonopoulos & Hall, 2016; Hanley
Santos & Coomber, 2017; Jennings, Patten, Kennedy, & Kelly, 2014;
Underwood, 2017; Zahnow, McVeigh, Ferris, & Winstock, 2017). Whilst
literature suggests that the most common reason for IPED use is to build
muscle, increase strength and/or lose weight, motivations for IPED use
now increasingly include a vast array of other reasons, including: sexual
enhancement, skin tanning, healing following injury, and increasing
confidence and self-esteem (Bates & McVeigh, 2016; Begley et al., 2017;
Cohen et al., 2007; Jennings et al., 2014; Kimergård & McVeigh, 2014;
Kraska, Bussard, & Brent, 2010; Underwood, 2017; Zahnow et al.,
2018).
In addition to this increase in, and diversification of, IPED users, the
supply of IPEDs has also become more widespread, with an ever-in-
creasing range of licit and illicit drugs and supplements available to
users (Antonopoulos & Hall, 2016; Coomber et al., 2015; Hanley Santos
& Coomber, 2017; Sagoe et al., 2015; Van Hout & Kean, 2015). As some
have demonstrated, this has also been facilitated by the growth of the
internet and online pharmacies (Coomber et al., 2015; Coomber &
Salinas, fc; Hall & Antonopoulos, 2016; van de Ven & Koenraadt, 2017).
As a result, individuals now frequently use a diverse range of substances
concurrently (Dodge & Hoagland, 2011; Sagoe et al., 2015). This in-
cludes the ‘stacking’ of various AAS, with Testosterone Enanthate,
Deca-Durabolin and Sustanon among the most popular varieties of AAS
(Antonopoulos & Hall, 2016; Bates & McVeigh, 2016; Kraska et al.,
2010); the use of substances to enhance the muscle-building properties
of AAS, such as human growth hormone (HGH) and insulin (Kanayama
& Pope, 2012; Kraska et al., 2010; Sagoe et al., 2015); and the use of
substances to combat the negative side effects of AAS use, such as sil-
denafil (e.g. Viagra) to treat erectile dysfunction, benzodiazepines to
improve sleep, and antioestrogens for conditions such as gynecomastia
(Hope et al., 2013; Jennings et al., 2014).
In addition to the above ancillary substance use, numerous studies
have reported IPED users’ concomitant use of illicit psychoactive sub-
stances (e.g. Antonopoulos & Hall, 2016; Begley et al., 2017; McVeigh &
Begley, 2017; Sagoe et al., 2015; Van de Ven et al., 2018). Since 2013,
annual surveys into IPED use carried out by researchers at Liverpool
John Moores University (Bates & McVeigh, 2016; Begley et al., 2017;
Chandler & McVeigh, 2014; McVeigh et al., 2015) have continually
demonstrated concomitant psychoactive substance use among their
sample of IPED users. Whilst reported rates have differed over the four
surveys – which is partly due to methodological differences – findings
from their most recent survey (Begley et al., 2017, p. 20) show that a
third (33 per cent) of their sample had used cannabis within the past 12
months, a quarter (25 per cent) had used cocaine, with one in six (14
per cent) using ecstasy and one in 12 (6.8 per cent) using amphetamine.
Importantly, whilst rates of concomitant psychoactive substance use
differ markedly between studies (e.g. Hope et al., 2013; Jennings et al.,
2014; Kanayama, Pope, Cohane, & Hudson, 2003; Sagoe et al., 2015),
IPED users consistently appear to consume illicit recreational drugs at
rates far in excess of general populations (e.g. Broadfield, 2017;
Substance Abuse & Mental Health Services Administration, 2017). Such
diverse polydrug-using repertoires pose a number of risks to users (see
Begley et al., 2017), in particular potential adverse psychophysical ef-
fects from the chemical interactions from AAS-related polypharmacy
(Sagoe et al., 2015, p. 17).
In order to increase the effectiveness of public health interventions
for IPED users, it is vital to further recognise their extensive poly-
substance use regimens (Evans-Brown, McVeigh, Perkins, & Bellis,
2012; Sagoe et al., 2015). Whilst the extant literature has provided
insight into some of these issues, there remains a scarcity of in-depth,
qualitative research that explores the nature, motivations and experi-
ences of IPED users, including, but not limited to, their IPED regimes,
polypharmacy, and using practices. Furthermore, many of the relevant
studies (see Sagoe et al., 2015) do not include illegal psychoactive drugs
in their assessment of polypharmacy among IPEDs users. Further re-
search of this type is thus needed in order to develop more targeted
interventions to address the public health issues that IPED users present
in the UK and internationally (Dunn, Mckay, & Iversen, 2014; Evans-
Brown et al., 2012; Hope et al., 2016; Iversen, Hope, & McVeigh, 2016;
McVeigh & Begley, 2017; van Beek & Chronister, 2015; van de Ven,
2016). This paper sets out to enhance empirical knowledge and un-
derstanding of polypharmacy among IPED users and the intersection of
IPEDs, diverted medication and illicit recreational drugs.
One of the means through which we can better understand IPED
users’ polypharmacy and using practices is to conduct further research
into the supply of IPEDs. As van de Ven and Mulrooney (2017) argue,
whilst there has been a recent surge of research into IPEDs, the majority
of this research has focused on their consumption, largely ignoring
methods of supply. Notwithstanding this, there is a general consensus
within the existing literature that the supply of IPEDs is – as is often the
case with other illicit substances (see Coomber & Moyle, 2014;
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Coomber, Moyle, & South, 2016) – most aptly characterised by a social
supply model (Coomber et al., 2015; Kraska et al., 2010; Maycock &
Howat, 2007; van de Ven & Mulrooney, 2017; Van Hout & Kean, 2015).
Social suppliers do not view themselves – and are not viewed by others
– as dealers per se (Coomber & Moyle, 2014; Coomber et al., 2015) but
rather as merely ‘helping out’ friends or acquaintances. Rather than
being commercially driven, social suppliers of IPEDs instead receive
status or ‘kudos’ in return (Antonopoulos & Hall, 2016; Christiansen
et al., 2017; Coomber et al., 2015; van de Ven & Koenraadt, 2017). In
support of this view, through their study of the IPED markets in the
Netherlands and Belgium, van de Ven and Mulrooney (2017, p.7) argue
that ‘dealing networks … are more likely to consist of friends or “friends
of friends”, tied together by threads of collective meaning’. The authors
posit that relationships between buyer and seller are built upon high
levels of trust and mutual respect, with IPED suppliers often educating
and mentoring users to reduce the potential harms of IPED use (van de
Ven & Mulrooney, 2017, p. 11; see also Maycock & Howat, 2007).
The social supply of IPEDs and, particularly, the mentor-mentee
relationship often forged by suppliers and users (see Antonopoulos &
Hall, 2016; van de Ven & Mulrooney, 2017; Van Hout & Kean, 2015)
serves to safeguard against risks from IPED use by educating novice
users on safer drug-using practices. In their research in North East
England, Antonopoulos and Hall (2016, p. 707) provide evidence of a
known IPED supplier refusing to sell to a novice gym user, as he did not
consider IPED use appropriate given his relatively short weightlifting
career and lack of adequate diet. This, the authors note, was considered
to represent a common approach by IPED suppliers, which is based on a
genuine interest in users’ health and wellbeing, and which further de-
monstrates the lack of commercial, profit-driven motives
(Antonopoulos & Hall, 2016).
Given its ‘socio-cultural embeddedness’, and the prerequisite of
cultural and technical knowledge to supply IPEDs (Fincoeur, van de
Ven, & Mulrooney, 2015; Maycock & Howat, 2007), research suggests
that the IPED market exists as a distinct entity, largely separated from
other illicit drug markets (Antonopoulos & Hall, 2016; Coomber et al.,
2015; Fincoeur et al., 2015; van de Ven, 2016; van de Ven &
Mulrooney, 2017). However, the expansion of the internet and the
growth of online marketplaces appears to have altered this in recent
years. Reflecting on the polydrug-using repertoires of many IPED users
(Begley et al., 2017; Hope et al., 2013; Jennings et al., 2014; Sagoe
et al., 2015; see above), Antonopoulos and Hall (2016, p. 704) argue
that such users ‘are the ideal-type of customer targeted by online sup-
pliers who deal in a range of pharmaceutical, performance-enhancing
and psychoactive drugs simultaneously’. The authors provide an ex-
ample of an individual with an extensive polydrug-using repertoire,
which included AAS, cocaine, anti-depressants and sleeping pills, who
purchased these substances from an online seller. Given the extensive
polypharmacy reported by IPED users examined above, it is hypothe-
sised here that we might begin to witness a convergence of these
markets, particularly given the extent of user-suppliers often found
within supply chains (see, for example, Coomber et al., 2015; Coomber
& Moyle, 2014; van de Ven & Mulrooney, 2017).
Support for this hypothesis is offered when considering Fincoeur
et al.’s (2015) findings. Examining the IPED markets in the Netherlands
and Belgium, the authors suggest that increased law enforcement efforts
have deterred social suppliers of IPEDs, who are exiting the market due
to the increased risk involved in suppling (Fincoeur et al., 2015, p.
244). As a result, the authors suggest that culturally embedded sup-
pliers are being replaced by profit-driven, commercialist dealers who
are more prepared to take risks in supplying IPEDs (Fincoeur et al.,
2015). In support of this assertion, the authors draw on research by De
Hon and Van Kleij (2005), who identified the presence of a ‘new’ IPED
dealer, ‘devoid of the socio-cultural attributes of “minimally commer-
cial dealers”’ (De Hon and Van Kleij, 2005 cited in Fincoeur et al., 2015,
p. 244). The displacement of social suppliers by commercially moti-
vated suppliers can have a number of significant implications for the
IPED market and its users, which includes the loss of expert advice and
the increase in supply of poor quality products (Fincoeur et al., 2015;
van de Ven, 2016).
Taken together, whilst the literature continues to suggest a dom-
inance of social suppliers of IPEDs and a largely distinct IPED market,
due to the above findings, along with consideration of the vast poly-
pharmacy of IPED users, there have been recent calls for further re-
search. In particular, to establish the extent to which commercially-
oriented suppliers are entering the IPED market (e.g. Fincoeur et al.,
2015) and the extent to which IPED markets have converged with other
drug markets. The research that follows provides evidence to suggest
that this picture is emerging in some localities, whereby commercially-
oriented dealers are supplying IPEDs in a marketplace intersected by
the supply of various licit and illicit substances and diverted medica-
tions.
Research methods and sample characteristics
The data presented here was collected via an ethnographic study of
an independent, non-corporate ‘bodybuilding gym’ in an anonymised
town in the north of England. Privileged access was afforded due to the
first author’s pre-existing ties to the gym owner (the study’s gatekeeper)
who was affiliated with a six-year ethnography of illegal drug markets
and offending careers (Salinas, 2018; Askew & Salinas, 2018). This
longstanding relationship and trust in the research process – including
confidence in our assurances around anonymity and confidentiality –
afforded a level of openness and insight seldom obtained in such a
sensitive research setting.
Four fieldworkers undertook 64 h of overt systematic observations
on site, recording conversations and observations via field notes and, in
the case of observations, digital photography.2 The research team
brought a breadth of experience necessary to the success of the re-
search, having previously conducted ethnographic studies on drug
markets and drug use, or else being experienced gym-goers with an in-
depth understanding of the subject area. Ethnographic fieldwork was
supplemented by 20 in-depth semi-structured interviews, up to three
hours in duration, with: (i) the gym’s owner and its duty manager –
both of whom were male IPED users and ‘commercial’ IPED suppliers;
(ii) a female personal trainer and IPED user; and (iii) 17 of the gym’s
male members who were recruited and interviewed directly on site – 16
of whom were IPED users (see Table 1).
IPED use was widespread; staff and member interviewees estimated
that between ‘70’ and ‘99.9’ per cent of the gym’s total 300–400
membership3 were IPED users. One interviewee – a semi-professional
rugby player – was currently serving an 18-month suspension for
doping, while another had used IPEDs to help compete in amateur
bodybuilding. However, most interviewees and people encountered
directly during ethnographic data collection were non-competitive
IPED users i.e. they did not compete in terms of performance (sports
such as powerlifting or football) or aesthetics (bodybuilding). None-
theless, the rigorous training and dietary regimes of our participants
meant most were ‘serious’ rather than merely ‘casual’ gym-goers.
Findings
The paper’s findings are presented in two broad thematic sections.
We begin by examining the intersection of drug use among our
2 The willingness among many of the study’s participants to be photographed
and filmed exercising, purchasing and using (often via intramuscular injection)
IPEDs, provides further testimony as to the level of trust afforded to the re-
search team.
3 Precise membership figures were unobtainable, as most attendees opted to
pay per training session and simply signed-in by hand, with just over 50 in-
dividuals paying via a formalised monthly membership system.
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participants before turning our attention to the intersection of the as-
sociated markets.
Intersection of substance use: polydrug-using repertoires
The data presented below illustrate the breadth of substances used
by the study’s participants. Sagoe et al. (2015) identified 13 classifi-
cations of substances used by anabolic-androgen steroid (AAS) users;
however, for the purpose of our analysis, we have subdivided poly-
pharmacy into three broader classifications based on their primary
functions: (i) drugs with an aesthetic function; (ii) drugs with a med-
icinal function; and (iii) drugs with a psychoactive function.
Drugs with an aesthetic function: combinations of, and oscillations between,
IPEDs
The IPED repertoire of many participants was extensive, and in-
dividuals often switched between different IPEDs over time and across
cycles. In support of existing literature (Antonopoulos & Hall, 2016;
Bates & McVeigh, 2016; Kraska et al., 2010; McVeigh et al., 2015), all
bar one of our user-participants reported the concurrent use (‘stacking’)
of various varieties of AAS – both oral and injectable. Across our
sample, there was no standardised stack, ratio or regimen of IPEDs,
with the choice of item(s), and frequency of use, dependent upon a
range of factors, including: the physiological outcome they hoped to
achieve (e.g. cutting, bulking,4 etc.); recommendations from other,
more experienced users, including gym staff and members; the desire to
locate a brand or combination/ratio that best suited their own parti-
cular metabolic or physical characteristics; and/or the availability of
items through their supply channels. As one IPED user noted:
I like a lot of Trenbolone, Acetate Propionate, stuff like that because
you get a little bit of size, you get some hardness, you stay lean and
strong. I’m not really a fan of your Deca [Durabolin] and your Sust
[anon] to give you size. Don’t get me wrong, I’ve taken them all…
[I’m currently taking] BDT… Boldenone, Decanoate and Test – I up
that [dosage] with a Test Max 450, which is just testosterone… [I’m]
taking a mil of each… in one syringe, then about 2 mil of Sustanon
in a separate syringe… [I’m taking that] every three days. And then
just the tablets… Oxymetholone Naps… They’re 50 mil tablets….
[After the current cycle I’m taking] two months off [IPEDs] then…
the whole course will change… I’ll be on the Tren, the Blends, the
Clomid and the Anavar and the Winstrol, just to cut-up for the
summer.
Floyd, gym member
Another interviewee similarly recalled an ever-changing combina-
tion of items used:
I try to change [IPEDs], I try to try something new. If something
works, that’s cool and I’ll remember it works and I’ll try use that
with something else. But I’m always going to try something to ad-
vance [my gains]… [My last IPED cycle] would’ve been Test 400
and Deca [Durabolin] 300 – both are injectable… Oh and Nap 50 s
[Oxymetholone] as well… They’re oral tablets. [I’ve also used]
Dianabol [Metandienone]; Winstrol [Stanozolol]; Naps; Halotestin
[Fluoxymesterone] – that’s nasty stuff… [I] had a little dabble with
that…; Sustanon; Test Enanthate; CYP [Cypionate]; Tren[bolone];
Deca [Nandrolone Decanoate]; Equipoise [Boldenone
Undecylenate].
Luke, gym member
Many in our sample reported the use of human growth hormone
(HGH), Melanotan (a synthetic hormone used to darken skin pigment),
“fat-burners” or diuretics (including Clenbuterol, T3s, T4s, T5s, T9s) in
conjunction with AAS to enhance their aesthetic appearance. Two in-
terviewees used insulin for image and performance enhancement;
however, most interviewees appeared concerned about the potential
hazards of this item, citing the death of a fellow gym member a year
earlier (as referenced by several interviewees). As one 10-year IPED
user noted, “There’s three lads doing it in here now… we’re trying to
tell them [not to use]… it’ll turn you diabetic if you take the wrong
dose” (Logan, gym member). Only one IPED was universally shunned:
Synthol – a site enhancement oil that temporarily increases the volume
of a muscle – an item described as “dirty” and a “cheat”.
Fieldworkers observed members and staff openly injecting them-
selves or others on the gym’s premises: in the changing room, the
sunbed area and, most commonly, the staff office. IPED use was not
merely condoned in this setting, but was instead actively facilitated and
supported by the gym and its staff members. Disinfectant wipes, sterile
Table 1
Interviewee descriptors.
Name Age Sex Age Commenced Training* Age Commenced IPED Use** Role(s) within ‘Behemoth Builder Gym’
Cesar 33 Male 21 24 Gym owner, gym manager, commercial-IPED supplier
Bernard 21 Male 15 18 Gym staff, duty manager, commercial-IPED supplier
Sandy 33 Female 14 31 Gym staff, personal trainer
Al 45 Male 15 42 Gym member
Apollo 35 Male 26 27 Gym member
Billy 23 Male 20 22 Gym member
Carl 24 Male 16 18 Gym member
Cass 25 Male 21 23 Gym member
Don 28 Male 25 Non-user of IPEDs Gym member
Floyd 29 Male 22 25 Gym member
Frank 35 Male 34 34 Gym member
Gaz 21 Male 17 19 Gym member
George 27 Male 17 20 Gym member
Jay 28 Male 17 20 Gym member
Logan 35 Male Unknown 24 Gym member
Luke 28 Male 18 18 Gym member
Mickey 20 Male 13 18 Gym member
Mo 24 Male 14 23 Gym member
Rick 34 Male 29 29 Gym member
Roy 28 Male 21 23 Gym member
* Whilst this is the age when participants first started training, many explained that they had taken periods of time off training, or had only started training
‘properly’ or ‘seriously’ in the last few years.
** Likewise, while this represents the age at which participants first used IPEDs, some participants explained that they had taken extended breaks from use.
4 ‘Cutting’ refers to the aim of losing fat; ‘bulking’ refers to the aim of gaining
muscle or general ‘size’.
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water and ‘sharps bins’ for the disposal of used needles were accessible
from the gym and were provided and disposed of by a local harm re-
duction service.
Drugs with a medicinal function: counteracting negative side-effects
Beyond the varying combinations of IPEDs outlined above, inter-
viewees also reported the concurrent use of ostensibly medicinal drugs
as a means of counteracting negative effects they were experiencing (or
anticipating) from AAS use (see Table 1). The negative effects reported
by these AAS users are widely documented within the literature (e.g.
Hope et al., 2013; Jennings et al., 2014; Sagoe et al., 2015) but in-
cluded, among other things, insomnia, erectile dysfunction, and gyne-
comastia (sore/swelling nipples/breasts). A number of interviewees
exemplified this:
You’ll be taking steroids and then you’ll be taking all the things to
counteract other things that are going wrong… You don’t realise
how much you’re actually taking; you’re not just taking steroids,
you’re taking loads of other things as well.
Sandy, gym personal trainer
A bit of Tren[bolone] it raises your body temperature… [I] can’t
fucking sleep with it at night… I still get it now [during the daytime,
when using] – sweating, like fuck… I go through… Valium… if I
ever need them [to aid sleep].
Apollo, gym member
hCG [human chorionic gonadotropin] – I’ll have that once a month
which helps prevent your sex drive from dropping. You can use stuff
like Proviron [Mesterolone] as well… From a young age [and as an
IPED user] I got – not addicted – but I used to have to take Viagra all
the time [as a result of steroid use].
Bernard, gym duty manager
It is noteworthy that several participants also reported using can-
nabis as a primarily medicinal supplement to AAS use (Table 2):
I’m on the juice [AAS], so I’m a little bit more touchy… I’ve gone to
smoking weed… and I have found that it has actually helped relax
me and I do think it goes well with steroids… [Smoking it] just
brings me down, calms me down to a mellow [state]. When you feel
like your head’s gonna go [through anger/agitation], you just have a
joint to chill out.
Carl, gym member
I’ll have a joint every now and then if I really can’t sleep [due to the
IPEDs].
Logan, gym member
I smoke weed at night and I take diazepam sometimes because Tren
[bolone] fucks my sleep up.
Cesar, gym owner
Among the IPED users with whom we spoke, all indicated the use
and necessity of these medicinal drugs concurrent to, or immediately
following, an AAS cycle, particularly anti-oestrogen items such as
Tamoxifen and post-cycle treatments such as hCG. Barring the use of
Viagra (used as a sexual enhancer) and Diazepam (used as a sleeping
aid), the use of AAS almost always preceded the use of these medicinal
drugs.
Drugs with a psychoactive function: concurrent recreational drug use
As with previous studies (e.g. Begley et al., 2017; Hope et al., 2013;
Kanayama et al., 2003; Sagoe et al., 2015), polysubstance use was
common among our sample, with over half of participants reporting the
use illegal psychoactive drugs alongside IPEDs. The most common
psychoactive substances used concurrently by this cohort of IPED users
were cannabis, cocaine and ecstasy. Barring the use of cannabis, which
some used on a daily basis, reported psychoactive drug use was gen-
erally recreational and intermittent. Nonetheless, there was evidence of
some high-risk patterned behaviour among several of the gym mem-
bers. For instance, a seven-year user of IPEDs, aged 28, described to us
his use of substances:
I’ve been flat out [using IPEDs] for seven months [Decanoate,
Testosterone and Sustanon], there’s been about a week or two on
about four occasions where I’ve not done them… [But I also] like to
‘play’ on weekends… I’m like a monster, a proper monster. I’ll sniff
up to a quarter [ounce of cocaine] most weekends… I’m going out
[to bars and nightclubs] with cocaine charged up and I’m going out
drinking at least 10–15 double vodkas [50ml measures each] and
whatever else – pints [of beer] and whatever else… MDMA, get on
the ‘Mandy’ and that sometimes… Then I go back to mine and then
it’ll be another double vodka.
Carl, gym member
This interviewee was not the only one to demonstrate particularly
high-risk patterns of drug consumption. Another interviewee used co-
caine daily and had sought treatment for what he considered to be
dependent use. Furthermore, two gym members encountered via eth-
nographic fieldwork were IPED users who smoked cannabis throughout
the day, including before gym training, and reported intermittently
using ecstasy, cocaine and, most notably, crack-cocaine.
Intersectional drug use: summary
The data indicates extensive drug-using repertories among our
participants, including ever-changing regimens of IPEDs, medicinal
drugs intended to mitigate their negative side effects, and, for over half
of the interviewees, psychoactive drugs. Generally speaking, drug using
repertoires followed a liner pathway, beginning with illegal psychoac-
tive drugs, followed – often years later – by IPEDs and diverted (or
counterfeit) medicinal drugs. Such findings may challenge heuristic
assumptions of dedicated gym-goers insofar as the self-administration
of so many drugs runs somewhat contrary to healthy or ‘clean’ living.
Nonetheless, these findings corroborate a trend identified in larger
surveys regarding relatively high rates of polypharmacy among IPED
users (e.g. Begley et al., 2017; Brennan et al., 2017; Sagoe et al., 2015)
and provide qualitative insight into the motives and patterns of such
use. In sum, this section has demonstrated that many of those fre-
quenting ‘Behemoth Builder Gym’ used a range of drugs for either an
Table 2
Substances used for countering the negative side-effects of IPEDs.
Substances Function(s)
Tamoxifen, Nolvadex, Letrozole, Arimidex Control/counter the body’s over-production of oestrogen
HCG and Clomid (clomiphene) Help restore or ‘kick-start’ the body’s own production of
testosterone post-AAS course
Viagra To counter erectile dysfunction or lull in libido
Cannabis, Valium, ZMA (supplement containing zinc monomethionine/aspartate, magnesium and vitamin B6),
‘Sleep Ease’ (Diphenhydramine Hydrochloride) or Diazepam
To aid sleeping and counter the ‘buzz’ felt from some
steroids.
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aesthetic, medicinal or psychoactive function. The gym thus provided
fertile ground for those able and willing to supply the evident demand
for these controlled/regulated drugs – it is here, to the intersection of
these markets, that we now turn our attention.
Intersection of drug markets: the gym as a trading bazaar
‘Behemoth Builder Gym’ provided a physical and social arena
through which members could source many of the aesthetic, medicinal
and psychoactive drugs listed above. Here, we provide an overview of
the observed market(s) subdivided into three thematic subsections: (i)
the supply of IPEDs and medicinal drugs by the gym; (ii) the supply of
IPEDs by gym members; and (iii) the trading of illegal psychoactive
drugs. In essence, this section describes how the gym functioned as an
illicit bazaar among its staff and members and, in so doing, illustrates
the extent to which legally controlled drugs were readily accessible to
those frequenting this environment.
The supply of IPEDs and medicinal drugs by the gym’s owner/management
For almost a decade, the gym’s owner and its duty manager had
jointly facilitated sales of IPEDs and medicinal drugs to many of its
members. Indeed, all except two of the 16 IPED-user interviewees
ranked the gym as their primary, though not necessarily exclusive,
source of IPED-related supplies. The vast majority of IPEDs listed by our
participants were available for purchase directly from the gym, in-
cluding various types of oral and intravenous AAS, HGH, melanotan, fat
burners, diuretics, and insulin, as well as medicinal items including:
post cycle treatments, anti-oestrogen items, sleeping aides (namely
Diazepam), and ‘Viagra’. The brazenness of this trade was evident from
field observations: customers entered the gym’s admin office, spoke
openly and unguardedly about IPEDs or medicinal drugs with the gym’s
members, owner and/or duty manager, browsed items on sale (all of
which were stored on site) and handed over money in exchange for
their chosen good(s).
Motives for supplying IPEDs were complex. On the one hand, the
gym’s owner and duty manager may be viewed as culturally embedded
within the body-building scene, and both spoke passionately of their
desire to help members attain their training goals, which ranged from
weight loss and toning, to competitive strongman and body-building
events. In addition to providing access to the gym and supplying the
‘gear’, they provided members with an array of ‘supplementary services’
(see Fincoeur et al., 2015), including guidance on exercise and training,
nutrition, IPED regimens, treatments for AAS side-effects, and post-
cycle treatments. Though some interviewees were somewhat sceptical
of the prescriptive advice given to members (e.g. what PCTs to take, at
what dose, and for how long) many evidently saw this as sage advice
and bought whatever drugs came recommended:
Interviewer: What about the Rip Blend [you’re currently taking]…
Do you know what’s contained in them?
Cass: No… I think it says on [the packaging] what’s in them, but I
don’t ever look.
Interviewer: So you take whatever they [owner and manager] give
you?
Cass: Yeah.
Interviewer: And where do you source your information on cycling?
Cass: The gym.
Interviewer: Just the gym?
Cass: Yeah.
(Cass, gym member)
However, the adoption of multiple roles – including mentor,
(unqualified) nutritionist, physician and, crucially, pharmacist (i.e.
supplier) – carried with it possible conflicts of interest.5 This is because
the gym’s primary source of revenue – estimated by the owner to be
roughly £1500 a week – came from the sale of IPEDs and medicinal
drugs (e.g. hCG). These sales were an intrinsic component of the gym’s
business model and indeed of greater commercial necessity than other
revenue streams such as legal supplements (e.g. protein) and mem-
bership fees. This juxtaposition is evident in the following quote, in
which the gym owner makes explicit reference to the gym’s financial
dependence on IPED sales:
Quite frankly, this gym wouldn’t be worth having if it didn’t sell
‘gear’… At the end of the day I’m a businessman and sometimes I
have bought stuff that’s not the best. I’ll say to my mates and my
members, “Look, it’s not the best but it’s cheap”. And sometimes
they’ll still buy it.
Cesar, gym owner
As the excerpt demonstrates, the gym owner was willing to supply
stock he judged to be substandard if consumers were content using it,
viewing himself, first and foremost, as a businessman. Similarly, the
gym’s duty manager alluded to simultaneous motives, indicating a de-
sire to support members achieve their goals whilst ensuring repeat
custom:
All the lads who come to the gym, you want them to look good, you
want them to come back to you for more so you want to give them
the best [‘gear’]. You’re not going to give them the shit stuff. You
want them to spend their money. You want them to come back and
look good.
Bernard, gym duty manager
Again, with his desire to give his members a quality service, the
duty manager might be viewed as a ‘minimally commercial’ supplier;
however, when considering that this desire was fuelled by a need for
repeat customers, this suggests a more direct economic motive. In short,
though the gym owner and duty manager were motivated to deal for
both socio-cultural and economic reasons, financial imperatives were of
paramount importance.
Gym members as ‘social’ and ‘minimal-commercial’ IPED suppliers
The supply of IPEDs was not the sole domain of the gym’s owner and
duty manager. Several gym members bought IPEDs from the gym and
resold these items to friends for no profit, thus falling into the category
of social supplier (c.f. Coomber et al., 2015; Kraska et al., 2010;
Maycock & Howat, 2007; van de Ven & Mulrooney, 2017; Van Hout &
Kean, 2015). One gym member explained his reasoning for supplying
IPEDs to a work colleague:
There’s a lad where I used to work. He wanted steroids… [He told
me] “It’s up to you, I can either get them from you, and you can help
me [inject] or I’ll get them from someone else and let them do it”… I
didn’t want anybody to fucking just sell him any shit and do fucking
anything to his head, so I was like “Fair enough, I’ll get it you and I’ll
do your jab [injection] for you”.
Apollo, gym member
Other gym members had bought wholesale at discount cost from the
gym and resold the items at a mark-up to outsiders (non-members) and
were thus considered ‘minimal commercial suppliers’. This practice and
its (at least partial) financial motive was less common than that of so-
cial supply – “there’s only about seven lads in here, at most, who make
money from selling on my stuff” (Cesar, gym owner). One interviewee
5 Parallels may be drawn with the United States’ pharmaceutical trade, where
doctors had previously been incentivised to prescribe certain forms of pain
relief drugs (Quinones, 2015).
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described how he initiated such sales:
I always try and get people on the gear [laughs]. I sell it myself so I’m
like “Get on this”. They’re always like “Ah, you look fucking well,
look at the size of you”. And I say “You could be like this too, I’ve got
some stuff for you”.
Roy, Gym member
There was also indirect evidence of unsanctioned sales undertaken
by some gym members on the premises, as this interviewee eluded to:
There’s a couple of guys who sell it here… A lot of the Eastern
Europeans that come here come and sell it…. They’re renowned for
getting really good stuff apparently.
Don, gym member
Our data indicates that a far broader range of actors were involved
in the IPED trade beyond simply the owner and duty manager. Though
a small number of gym members profited financially from buying and
selling “like 10 bottles at a time and selling them to other people from
other gyms” (Luke, gym member), most were social suppliers ‘sorting
friends’ in their social networks for no profit.
The market for psychoactive drugs and other criminal items
‘Behemoth Builder Gym’ also functioned as a site through which
informal, often illegal, deals were arranged or facilitated. Whilst
members bought and sold a range of goods6, the primary commodities
being traded were illegal psychoactive drugs. Interviews and field ob-
servations indicate that a number of gym members sold illegal psy-
choactive drugs, including cocaine, ketamine and cannabis. They op-
erated as ‘closed market’ drug dealers, supplying drugs to people within
their social networks, including to fellow gym members who were often
considered friends. Illegal psychoactive drugs (barring cannabis) were
forbidden from the gym’s premises, yet individuals could still establish
customer contacts or arrange deals at the gym.
I sell a lot of weed [cannabis]… A few of the lads here [in the gym]
buy from me – [they’re] mates of mine really.
Billy, gym member
You’ll get some here asking [for cocaine] every now and again… I’ve
never sold anything actually in the gym. I don’t even take it with me
into the gym when I’m training… [but] I dropped off [cocaine] to
[three cocaine customers and fellow gym-members] last week.
Ralphy, gym member, fieldwork encounter
When I used to sell [cocaine] big fuckin’ time [as a wholesaler] I had
a few of my members getting it from me [lists several gym members]
… Lots of people I know have had something ‘on the side’ at some
point or another… There’s a few here now selling bits and pieces.
Cesar, gym owner
Gym members appeared reticent and more guarded when discussing
the supply of illegal psychoactive drugs – at least when in the presence
of our researchers. During fieldwork, we observed the use of coded
language indicative of drug sales – “When do you want that green paint
[cannabis] dropping off? Still a full one [unknown unit] you’re after?”.
Such subversion was not employed when members and staff discussed,
bought or sold IPEDs, indicating a disjuncture between how individuals
ranked social (stigma) and legal concerns for these drugs. This point is
of significance for the ensuing discussion.
It is notable that the gym’s very inception was dependent upon
criminal revenues earned from the ‘traditional’ illegal drug trade. As
alluded to in the previous quote, the gym’s owner had successfully
wholesaled cocaine for several years. Revenues from its sale (as much as
£3000 net profit per week) had provided the capital necessary to es-
tablish, keep afloat and develop the gym as an ongoing business during
its early (and financially turbulent) years. When the opportunity
emerged, he transitioned from selling cocaine to IPEDs and related
medications. This, he noted, was significantly less risky than selling
other illicit substances:
I’m doubling my investment on loads of the stuff… It’s mad, I’m
selling to that many people… [It’s] much safer than selling coke…
[IPEDs are] not a priority for the police and it’s harder for them to
try prove I’m selling [IPEDs]: we’d just say it’s all ours – me, [the
duty manager], me mates – and just tell them we’re storing it here so
it’s away from our missus [sic] and families… It’s not illegal to have
it for your own use [unlike cocaine].
Cesar, gym owner
Though far less pronounced, the trading of illegal psychoactive
drugs was facilitated indirectly by the gym. Illegal psychoactive drugs
do not appear to have been sold directly on the gym’s premises, yet the
fraternity that existed among the gym members provided an abundance
of social contacts through which closed market drug dealing could
occur outside of these premises.
Intersectional drug markets: summary
As this section has demonstrated, ‘Behemoth Builder Gym’ was more
than merely a functional space for physical exercise. It acted as an
‘entrepreneurial area’ (Hobbs, 1995, p. 114) through which the com-
mercial or social supply of drugs could be undertaken. As such, the gym
functioned in much of the same way the traditional British pub once
had (Hobbs, 1995): it provided a social setting in which a pre-
dominantly male clientele essentially ‘hung out’ away from occupa-
tional or familial commitments, and it helped facilitate an expansive,
seemingly fraternal, social network through which the demand for il-
licit goods could be met. The three broad categories of drugs discussed
here – namely IPEDs, medicinal and psychoactive drugs – were all
readily accessible to those who frequented this environment. The cen-
trality of IPEDs and medicinal drugs – both in terms of its use and trade
– cannot be overstated. In contrast, the trade in illegal psychoactive
drugs was somewhat subverted and not directly tied to the gym’s core
business, though nevertheless present.
Discussion and conclusion
IPED users and markets are often depicted in the literature and
policy discussion as distinct entities, as outliers from traditional illicit
drug-using populations and supply markets (e.g. Antonopoulos & Hall,
2016; Coomber et al., 2015). The findings presented here challenge this
discourse by elucidating the intersectionality that exists across IPEDs,
diverted medication and illicit substance use. The use of substances
amongst this sample of body builders transcended IPEDs to encompass
a much broader cocktail of substances. An estimated 70 per cent of the
gym’s 300–400 members used IPEDs. Among our sample, all who used
IPEDs concomitantly used diverted medication, and over half used il-
legal psychoactive drugs. Moreover, the use of illegal psychoactive
drugs had, in all cases, preceded the use of IPEDs and diverted medi-
cation. The IPED users in our sample were thus not a distinct drug user
population, but should be more appropriately viewed as ‘traditional’,
recreational drug users whose drug-using repertoires had extended to
incorporate drugs that served an aesthetic function.
As many within the field have stressed (e.g. Dunn et al., 2014;
Evans-Brown et al., 2012; Hope et al., 2013, 2016; Iversen et al., 2016;
McVeigh & Begley, 2017; van Beek & Chronister, 2015; van de Ven,
2016; Van Hout & Kean, 2015), in order to develop more targeted
6 For example, one fieldworker observed the gym owner purchasing vitamin
drinks (Fortisip) from individuals whom the manager claimed were heroin users
who acquired them weekly on prescription; these were then resold to members.
Similarly, fieldworkers observed a couple (non-members) bartering with the
gym manager over tools they had ostensibly stolen and were trying to sell him.
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interventions for IPED users, it is necessary to gain a better under-
standing of their polypharmacy and using practices. The uncovering of
the extreme polysubstance use documented through this paper is sig-
nificant and necessitates a review of existing harm reduction advice for
IPED users that goes beyond advice on safe injection practices and takes
into consideration the full range of substances that IPED users may be
consuming. It is not yet known what the potential health implications
are from such extensive drug-using repertoires nor of the chemical in-
teractions these drugs have upon one another (Sagoe et al., 2015).
Intersectionality was also present in relation to drug supply, with
many participants sourcing substances via the gym owner, duty man-
ager and gym members. IPEDs, diverted medication and illegal psy-
choactive drugs were all readily accessible to those attending the gym.
Our findings indicate that ‘Behemoth Bodybuilder Gym’ acted as a focal
point for a significant proportion of members’ social interactions and –
in doing so – functioned as an informal trading bazaar insofar as these
otherwise illegal (or, at the very least, deviant) transgressions were
largely accepted, indeed normalised, within this environment. The gym
was as much a space for leisure and for socialisation as it was a space to
hone one's physique. Given that much of the broader drug trade is
predicated on informal arrangements between friends and friends-of-
friends (Lader, 2015; Substance Abuse & Mental Health Services
Administration, 2010, p. 28), it is perhaps unsurprising, then, that in-
dividuals utilised social networks facilitated by the gym to source and
supply these illegal drugs. This symbiosis between supplier and con-
sumer necessitates a closer assessment of IPED markets. The accessi-
bility of such an array of drugs within this social environment is likely
to have direct bearing on the polypharmacy observed among the gym’s
members. This is partly because opportunities to use drugs increase
correspondingly with their availability (Bennett & Holloway, 2007 p.
256-7).
Our study contributes to knowledge regarding the evolution and
displacement of market actors in response to the opportunities, costs
and benefits associated with illegal drug supply (see Aitken, Moore,
Higgs, Kelsall, & Kerger, 2002; Garzón & Bailey, 2016). Fincoeur et al.
(2015) demonstrate the movement of ‘minimally commercial’ suppliers
out of the IPED market in response to heightened risks from targeted
law enforcement efforts. They hypothesise that ‘as the [IPED] market
becomes more lucrative and subject to increasing attention from the
authorities, minimal commercialist dealers are being replaced by more
overtly criminal types driven by profit, willing to take risks’ (Fincoeur
et al., 2015, p. 244). Our case study corroborates this assertion, and
demonstrates the movement of a commercially-oriented, ‘traditional’
drug supplier into the IPED market. As noted elsewhere (e.g. Fincoeur
et al., 2015; van de Ven, 2016), the displacement of culturally-em-
bedded suppliers by commercially-oriented suppliers carries with it a
number of risks, which includes the loss of expert advice and the in-
crease in supply of poor quality products. This is particularly proble-
matic when considering the conflict of interest of the gym owner as
evidenced through this paper.
This study also provides a more nuanced insight into the motiva-
tions of ‘traditional’, commercial drug dealers entering the IPED market
that extends beyond simple profit-making opportunities. For the gym
manager in this study, whilst the decision to supply IPEDs was, first and
foremost, commercially motivated, there was an added dimension
concerned with the lower risks associated with the supply of these
substances in comparison to other illicit drugs. This is considered to be
due to current UK classification and sentencing guidelines. In the UK,
for example, despite many IPEDs being classified as class C substances,
the typical possession offence of up to two years’ imprisonment and/or
an unlimited fine for a class C substance does not apply under the 1971
Misuse of Drugs Act. This contrasts with a sentence of up to seven years
for possession of class A substance (e.g. cocaine, MDMA) or 16 years for
possession with intent to supply (Sentencing Council: Drug Offences
Definitive Guideline, 2012).
This finding also raises important questions for policy in the face of
more punitive approaches to IPED use being adopted in other jur-
isdictions. For example, in Queensland, Australia, anabolic steroids
were rescheduled in 2014 as a schedule-one substance to sit alongside
other substances such as crystal methamphetamine, cocaine and heroin.
The potential punishment for intent to supply is up to 25 years’ im-
prisonment. However, increased scheduling aimed at deterring drug
dealers and organised crime invariably carries increased sentences for
possession, therefore potentially criminalising a growing number of
otherwise law-abiding IPED users. Increasing punitive sanctions toward
IPEDs will likely heighten the stigma associated their use which could
result in fewer IPED users accessing treatment. In light of the potential
for harm that exists with such a plethora of polysubstance use ex-
emplified in our study, the potential negative effects of reclassifying
IPEDs needs to be considered.
Finally, a note on methods. The ethnographic nature of this research
project illustrates the utility of this methodological approach that goes
beyond existing knowledge generated through quantitative methods
(Bates & McVeigh, 2016; Chandler & McVeigh, 2014; McVeigh et al.,
2015). The discussion of the gym as a place to go to after work and
before going home presents the gym as a prominent site for socialisa-
tion and relaxation, performing similar functionality and purpose as the
traditional English public house. The rich data presented here in this
traditional gym setting underscores the importance of physical social
settings. As Hobbs (1995, p. 106) has observed in reference to criminal
entrepreneurship: ‘These arenas support instrumental networks that
function as enabling environments for a plethora of money-making
opportunities, some of which will be either partly or wholly criminal’.
With this in mind, we assert that scholars should resist the temptation
to concentrate the empirical lens solely on the new and novel. Despite
the increased prevalence of internet-facilitated IPED sales in recent
years (Hall & Antonopoulos, 2016) survey data indicates that less than a
quarter of users currently obtain IPEDs via these online outlets (Begley
et al., 2017). Social supply networks — such as friends, trainers and
‘dealers’ — continue to dominate the IPED market. The expansion of the
IPED consumer-base, the dominance of social supply markets and the
emergence of more commercially minded suppliers warrants further in-
depth studies of these ever-evolving markets.
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